Mode
Text Size
Log in / Sign up
Phase 1 N=20 Randomized

PPI and Clopidogrel Response

Drug Interaction

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Mar 2012
Primary outcome: Primary: Platelet Function as Assessed by the P2Y12 Reactivity Index — 56.1; 61.6; 56; 61 Percentage of platelet reactivity index

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
omeprazole and pantoprazole (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Florida
Primary completion
Aug 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Platelet Function as Assessed by the P2Y12 Reactivity Index
56.1; 61.6; 56; 61; 48.8; 61.0

Summary

Clopidogrel, in combination with aspirin, is currently the recommended treatment for secondary prevention of ischemic events in high-risk patients and for prevention of coronary artery stent thrombosis. Patients receiving aspirin and clopidogrel are frequently treated with proton pump inhibitors, such as omeprazole or pantoprazole, in order to prevent the risk of gastrointestinal bleeding, accorded to guidelines. An interaction between proton pump inhibitors and clopidogrel has been suggested, which may lead to a decrease of clopidogrel effects. It remains unclear whether this interaction between PPIs and clopidogrel might be a class effect or if this may be affected by timing regimen. The objectives of this two-phase investigation are: 1. to compare clopidogrel platelet inhibitory effects when taken at the same time versus separated at least 8 hours from omeprazole administration. 2. to compare clopidogrel-induced inhibitory effects when taken at the same time versus staggered at least 8 hours from pantoprazole administration.

Eligibility Criteria

Inclusion Criteria

  • Healthy volunteers aged between 18 and 75 years

Exclusion Criteria

  • Known allergies to clopidogrel or omeprazole.
  • Blood dyscrasia or bleeding diathesis.
  • Recent antiplatelet treatment ( 2mg/dL.
  • Baseline ALT >2.5 times the upper limit of normal.
  • Pregnant females.
  • Patients taking omeprazole or any H2 antagonist or proton pump inhibitors
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01170533). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search